Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab

por Corrêa, Tatiana Strava, Matos, Gustavo Duarte Ramos, Segura, Marcos, dos Anjos, Carlos Henrique
Publicado 2018

Targeting PARP1 to Enhance Anticancer Checkpoint Immunotherapy Response: Rationale and Clinical Implications

por Wanderley, Carlos Wagner S., Correa, Tatiana Strava, Scaranti, Mariana, Cunha, Fernando Queiroz, Barroso-Sousa, Romualdo
Publicado 2022

What can we learn from more than 1,000 Brazilian patients at risk of hereditary cancer?

por Leite, Ana Carolina Rathsam, Suzuki, Daniele Assad, Pereira, Allan Anderson Lima, Machado, Natalia Polidorio, Barroso-Sousa, Romualdo, Correa, Tatiana Strava, Moura, Fernanda Cesar, Morbeck, Igor Alexandre Protzner, Gumz, Brenda Pires, Faria, Luiza Dib Batista Bugiato, Fernandes, Gustavo dos Santos, Sandoval, Renata Lazari
Publicado 2022

Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study

por Oliveira, Leandro Jonata Carvalho, Megid, Thais Baccili Cury, Rosa, Daniela Dornelles, Magliano, Carlos Alberto da Silva, Assad, Daniele Xavier, Argolo, Daniel Fontes, Sanches, Solange Moraes, Testa, Laura, Bines, José, Kaliks, Rafael, Caleffi, Maira, de Melo Gagliato, Debora, Sahade, Marina, Barroso-Sousa, Romualdo, Corrêa, Tatiana Strava, Shimada, Andrea Kazumi, Batista, Daniel Negrini, Musse Gomes, Daniel, Cesca, Marcelle Goldner, Gaudêncio, Débora, Moura, Larissa Matos Almeida, de Araújo, Julio Antonio Pereira, Katz, Artur, Mano, Max Senna
Publicado 2022